BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical
POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC ® with Venture Medical, LLC , the Company’s exclusive sales and marketing partner. The launch is scheduled to commence in the fourth quarter and will cover every Medicare Administrative Contractor (MAC) region across the United States.
Jason Matuszewski, CEO of BioStem Technologies Inc., commented: “This is a pivotal moment for BioStem Technologies. With nationwide Medicare reimbursement, Vendaje AC ® becomes our second product available to patients across all 50 states. The launch of Vendaje AC ® underscores our commitment to delivering innovative wound care solutions for patients suffering from chronic, non-healing wounds. We’re excited to collaborate with Venture Medical once again, whose partnership was instrumental in the success of AmnioWrap2 ® . Together, we’re expanding access to cutting-edge treatments that make a real difference in patient outcomes.”
John Schroeder, CEO of Venture Medical, LLC, added: “With countless graft products available today, we’re proud to partner with BioStem Technologies, a company that prioritizes clinical efficacy in everything they do. Vendaje AC ® , manufactured using the innovative BioREtain ® process, retains the critical elements of placental tissue—structural components, growth factors, and anti-inflammatory cytokines—that are essential for effective wound healing. This breakthrough allows us to offer healthcare providers and Medicare beneficiaries a powerful, reimbursable solution tailored to meet the needs of patients with non-healing wounds. Together, we’re bringing a meaningful solution to those who need it most.”
About Vendaje AC ® :
Available by prescription through healthcare providers in all 50 states, Vendaje AC offers patients with non-healing wounds an advanced wound care option that acts as a protective barrier or covering to provide an environment for wound healing and closure. Vendaje AC is a thicker human connective tissue matrix comprised of dehydrated amniotic/chorionic tissue. Manufactured using BioStem’s patented six-step proprietary BioREtain ® process, Vendaje AC naturally contains extracellular matrix scaffolding, which provides mechanical protection and functional support for cell attachment, growth factors that help modulate proliferation and angiogenesis, and cytokines that inhibit inflammatory effects, all of which are critical in aiding the body’s natural healing cascade.
Healthcare providers or patients interested in learning more about Vendaje AC allografts can visit: https://biostemtechnologies.com/vendaje-ac-2/ .
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE , and follow us on Twitter and LinkedIn .
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap 2 ™, VENDAJE ® , VENDAJE AC ® , and VENDAJE OPTIC ® . Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn .